相关实验视频

Updated: Jun 10, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

自然产品目标识别的最新策略:探索慢性炎症及其他疾病的应用

Xian Pan^1,2, Shan Jiang^1,2, Xinzhuang Zhang^1,2

¹State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Jiangning Industrial City, Economic and Technological Development Zone of Lianyungang, Lianyungang, China.

British journal of pharmacology

|October 21, 2024

概括

自然产品为药物发现提供了多样化的生物活性,特别是在炎症和癌症中. 本次审查强调了确定其目标以推进复杂疾病治疗的策略.

科学领域:

自然产品药物发现自然产品药物发现
药品化学药品化学是一个
药理学药理学是指药理学的学科.

背景情况:

自然产品是药物发现的关键来源,特别是用于治疗感染,炎症和癌症,因为它们的复杂结构和多样化的生物活性.
慢性炎症与许多疾病有关,包括癌症和神经退行,需要有效的治疗策略.
确定天然产品的具体目标对于了解它们的作用机制,促进临床进展和发现新药点至关重要.

研究的目的:

在慢性炎症的背景下,在过去五年中审查和综合天然产品标识策略.
强调目标解密的重要性,以促进基于天然产品的药物发现,特别是复杂疾病.
为了突出由于多药学方法的兴起,对目标识别方法的需求日益增加.

主要方法:

用于早期目标发现和预测化合物结合位点的计算方法.
蛋白质学驱动的方法用于精确的目标划分和识别.
实验生物学技术用于强大的目标验证和深入的机制研究.

主要成果:

最近 (过去5年) 对慢性炎症中天然产品标识策略的全面概述.
计算,蛋白质和实验方法的整合为目标解卷提供了一个多方面的策略.
这些策略提高了药物发现和开发的效率,使得更好的目标选择和验证.

结论:

有效的天然产品目标识别对于阐明作用机制和推动临床发展至关重要.
结合计算和实验方法的先进策略是克服自然产品药物发现挑战的关键.
成功的目标解加速了慢性炎症和其他复杂疾病的新疗法开发.

关键词:

化学蛋白质组的化学物质.慢性炎症性慢性炎症性没有标签的 label-free.自然产品是自然产品的产品.目标识别目标识别

更多相关视频

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...